

Conference Market Analysis on World Summit on Oncology & Oncologists

Prof. Liane Deligdisch

E-mail: liane.deligdisch@mountsinai.org

Cancer is a disease characterized by uncontrolled cell proliferation. There are more than 100 types of cancer. The most widely recognized reasons for disease passing are malignant growths of Lung (1.69 million deaths), liver (788 000 deaths), Colorectal (774 000 deaths), Stomach (754 000 deaths) and Breast (571 000 deaths) which accounts for nearly half of new cases per year. Lung cancer, which is highly correlated with cigarette smoking, is responsible for more deaths than any other form of cancer. Cigarette smoking and other environmental factors are associated with the majority of cancers.

The kinds of cancer we expect to increase the most are:

Melanoma (the deadliest kind of skin cancer) in white men and women.

Prostate, kidney, liver, and bladder cancers in men.

Lung, breast, uterine, and thyroid cancers in women.

Cancer is among the leading causes of death worldwide. In 2012, there were 14.1 million new cases and 8.2 million cancer-related deaths worldwide. The number of new cancer cases per year is expected to rise to 23.6 million by 2030. The most recent SEER Cancer Statistics Review, released in April 2019, shows that cancer death rates decreased by 1.8% per year among men from 2006 to 2015, 1.4% per year among women from 2006 to 2015 and 1.4% per year among children ages 0–19 from 2011 to 2015.

Global Oncology/Cancer drugs Market is expected to garner \$111,938.4 million by 2020, registering a CAGR of 7.1% during the forecast period 2014 to 2020. Recent progress in biological therapies has widened the scale of therapeutic targets for cancer treatment with the identification of tumour cell specific genes. The number of approved cancer therapies continues to rise. The continued rise and impact of immune-oncology has been largely centred on the PD-1 and PD-L1 checkpoint inhibitors, which have broad efficacy across solid tumours and are used across 23 different tumour types. Overall, the global market for oncology therapeutic medicines will reach as much as \$200 billion by 2022, averaging 10–13% growth over the next five years, with the U.S. market reaching as much as \$100 billion by 2022, averaging 12–15% growth.

In 2019, the global cancer therapy market was valued at USD 136,254.35 million, and is estimated to be valued at USD 220,701.26 million in 2024, witnessing a CAGR of

8.37%. Factors that are driving the market growth include

- Increased Patient Assistance Programs (PAPs)
- Increased government initiatives for cancer awareness
- Rising prevalence of cancer worldwide
- Strong R&D initiatives from major research in Cancer

Target Therapy Segment is expected to show the Fastest Growth in the Forecast Period

The target therapy segment is expected to show the highest CAGR of 9.68% during the forecast period. The target therapy basically includes hormone therapies, angiogenesis

Inhibitors, immunotherapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, and toxin delivery molecules. Targeted therapy is getting great importance due to its high specificity toward cancerous cells, while eliminating the toxicity to off-target cells.

The Blood cancer segment is believed to account for the largest market size over the forecast period. This is majorly attributed to the higher and continuously increasing prevalence of breast cancer across the world. Over 2,66,120 new cases of invasive blood cancer are expected to be diagnosed in men, women, small children in the US, as per estimated by the Blood Cancer Organizations in 2019 along with 63,960 new cases of non-invasive (in situ) blood cancer.

North America currently dominates the market for cancer therapy. This region is expected to increase its market share in the future, owing to the increased adoption of cancer therapy. The United States holds majority of the market in the North American region, due to the rising prevalence of cancer in the country. In 2016, 1.6 million people suffered from cancer, and around 0.5 million people died from cancer, as reported by the National Cancer Institute (NCI). This figure indicates that the prevalence of cancer is rapidly increasing in the United States.

Snapshot of Asia-Pacific oncology/cancer drugs market

Asia-Pacific oncology/malignant growth drugs advertise has high development potential, attributable to ascend in disease mindfulness over the locale and increment in R&D speculation. Besides, this area presents prominent open doors for the financial speculators and speculators, as the created markets are relatively soaked. Also, increment in extra cash; flood in inquire about, advancement, and development exercises; and ascend in mindfulness identified with various tumors are some different elements, which contribute toward the development of the oncology/malignancy drugs advertise in this locale. Likewise, across the board pervasiveness of specific malignant growths, such stomach disease, and nearness of tremendous geriatric populace in nations, for example, Japan drive the market development in this locale.

The report gives a broad aggressive examination and profiles of the key market players, for example, AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, f. Hoffmann-La Roche Ltd., Johnson and Johnson (Janssen Global Services, LLC), Merck and Co., Inc., Novartis AG, and Pfizer Inc.. Different players in the worth chain incorporate Sanofi, Amgen Inc. Bayer AG, and Exelixis, Inc.

Key Benefits for Oncology Drugs Market:

- This report involves a definite quantitative investigation alongside current oncology/malignant growth drugs showcase patterns of the oncology/disease drugs advertise from 2017 to 2025 to recognize the common open doors alongside key appraisal of the worldwide oncology/malignancy drugs showcase.
- The oncology/malignant growth drugs showcase figure is contemplated from 2018 to 2025.
- Oncology/malignancy drugs showcase size and estimations depend on an extensive examination of key advancements in the oncology/disease drugs industry.
- A subjective investigation dependent on creative items encourages key business arranging.
- The improvement procedures embraced by the key market players are enrolled to comprehend the aggressive situation of the worldwide oncology/disease drugs advertise.

Oncology Drugs Key Market Segments:

By Drug Class Type

- Chemotherapy
- Targeted Therapy
- Immunotherapy (Biologic Therapy)
- Hormonal Therapy

By Indication

- Lung Cancer
- Stomach Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Esophagus Cancer
- Cervical Cancer
- Kidney Cancer
- Bladder Cancer
- Other Cancers

By Region

North America

- U.S.
- Canada
- Mexico

Europe

- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe

Asia-Pacific

- India
- China
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific

LAMEA

- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA